S M Domchek
Overview
Explore the profile of S M Domchek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rowlands C, Allen S, Balmana J, Domchek S, Evans D, Hanson H, et al.
Ann Oncol
. 2024 Jul;
35(10):892-901.
PMID: 38986768
Background: Germline genetic testing, previously restricted to familial and young-onset breast cancer, is now offered increasingly broadly to patients with 'population-type' breast cancer in mainstream oncology clinics, with wide variation...
2.
Sessa C, Balmana J, Bober S, Cardoso M, Colombo N, Curigliano G, et al.
Ann Oncol
. 2022 Oct;
34(1):33-47.
PMID: 36307055
No abstract available.
3.
Geyer Jr C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al.
Ann Oncol
. 2022 Oct;
33(12):1250-1268.
PMID: 36228963
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic...
4.
Hodgson D, Lai Z, Dearden S, Barrett J, Harrington E, Timms K, et al.
Ann Oncol
. 2021 Sep;
32(12):1582-1589.
PMID: 34500047
Background: Presence of a germline BRCA1 and/or BRCA2 mutation (gBRCAm) may sensitize tumors to poly(ADP-ribose) polymerase (PARP) inhibition via inactivation of the second allele, resulting in gene-specific loss of heterozygosity...
5.
Robson M, Tung N, Conte P, Im S, Senkus E, Xu B, et al.
Ann Oncol
. 2019 Jan;
30(4):558-566.
PMID: 30689707
Background: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm)...
6.
Telli M, Stover D, Loi S, Aparicio S, Carey L, Domchek S, et al.
Breast Cancer Res Treat
. 2018 May;
171(1):21-31.
PMID: 29736741
Purpose: Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with...
7.
Han H, Dieras V, Robson M, Palacova M, Marcom P, Jager A, et al.
Ann Oncol
. 2017 Oct;
29(1):154-161.
PMID: 29045554
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the antitumor activity...
8.
Matulonis U, Penson R, Domchek S, Kaufman B, Shapira-Frommer R, Audeh M, et al.
Ann Oncol
. 2016 Mar;
27(6):1013-1019.
PMID: 26961146
Background: The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore...
9.
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott R, McGuffog L, et al.
Br J Cancer
. 2012 Jun;
106(12):2016-24.
PMID: 22669161
Background: The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB)...
10.
Kossman D, Williams N, Domchek S, Kurzer M, Stopfer J, Schmitz K
J Appl Physiol (1985)
. 2011 Sep;
111(6):1687-93.
PMID: 21903887
Experimental and clinical data support a role for estrogens in the development and growth of breast cancer, and lowered estrogen exposure reduces breast cancer recurrence and new diagnoses in high-risk...